Senores Pharmaceuticals Limited today announced that it has received marketing authorizations from the Philippine Food and Drug Administration (FDA) for a basket of 10 products across Therapies like Cardiovascular, CNS, and Pain management, etc.

This milestone marks a significant step in the company’s strategy to expand its footprint in Southeast Asia and enhance access to affordable healthcare.

The approvals provide Senores Pharmaceuticals with a strong platform to serve the Philippines. The market size of these particular drugs in the Philippines is valued at US $23 million, underscoring the immense opportunity for growth and patient impact.

“These approvals reaffirm our commitment to delivering high-quality, affordable treatments for patients,” said Swapnil Shah, Managing Director of Senores Pharmaceuticals.

“Philippines is a critical market in our regional expansion strategy, and this achievement strengthens our position as a trusted partner in advancing healthcare.”

With these regulatory endorsements, strong manufacturing capabilities, Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region, leveraging its expertise, global partnerships, and uncompromising quality standards to improve treatment outcomes and broaden patient access.